PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31957305-7	2020	Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan).	pyrazolanthrone	213-221	nicotinamide phosphoribosyltransferase	Homo sapiens	0-8	
31957305-10	2020	Hypoxia, hypoxia with HBO and exogenous addition of AngII also increased promoter transcription to visfatin; SP600125 and losartan blocked this activity.	pyrazolanthrone	109-117	nicotinamide phosphoribosyltransferase	Homo sapiens	99-107	
24378536-6	2014	Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125.	pyrazolanthrone	246-254	nicotinamide phosphoribosyltransferase	Homo sapiens	0-8	
28097126-10	2016	Administration of JNK inhibitor SP600125 or ROS scavenger tocopherol with TMZ and NAMPT inhibitors substantially attenuated the sensitization of NAMPT inhibitor on TMZ antitumor action.	pyrazolanthrone	32-40	nicotinamide phosphoribosyltransferase	Homo sapiens	82-87	
28097126-10	2016	Administration of JNK inhibitor SP600125 or ROS scavenger tocopherol with TMZ and NAMPT inhibitors substantially attenuated the sensitization of NAMPT inhibitor on TMZ antitumor action.	pyrazolanthrone	32-40	nicotinamide phosphoribosyltransferase	Homo sapiens	145-150	
21542902-10	2011	Addition of SP600125 and TNF-alpha monoclonal antibody 30 min before HBO abolished the DNA-protein binding activity and visfatin promoter activity induced by HBO.	pyrazolanthrone	12-20	nicotinamide phosphoribosyltransferase	Homo sapiens	120-128